Cadre Holdings Discloses $34.5M CEO Expense Reimbursement, Significant Potential Dilution, and Board Changes
Summary
Cadre Holdings' definitive proxy statement reveals over $34.5 million in 'unallocated expense reimbursement' for its CEO, significant potential dilution from equity plans, and material related-party transactions with a CEO-owned entity, alongside changes to its Board of Directors.
Key Events
-
CEO Received Over $34.5 Million in Expense Reimbursement
CEO Warren B. Kanders' 2025 compensation included $34,531,948 for 'unallocated expense reimbursement,' a highly unusual and substantial amount.
-
Significant Potential Dilution from Equity Plans
As of December 31, 2025, 9,683,220 shares remained available for future issuance under equity compensation plans, representing a potential dilution of approximately 22.6% of current outstanding shares.
-
Material Related-Party Transactions Disclosed
The company paid $3 million to Kanders & Company, a firm solely owned by CEO Warren B. Kanders, for support related to two acquisitions in 2025 and 2026.
-
Board of Directors Changes Proposed
Two current directors, Deborah A. DeCotis and Gianmaria C. Delzanno, are not nominated for re-election, while Mary Kissel and former director Nicholas Sokolow are proposed as new board members.
Analysis
This definitive proxy statement reveals several significant corporate governance and compensation issues that could negatively impact investor sentiment, especially with the stock trading near its 52-week low. The most striking disclosure is the over $34.5 million in 'unallocated expense reimbursement' for CEO Warren B. Kanders in 2025, which is an exceptionally large compensation component. Additionally, the company's equity compensation plans have a substantial 22.6% potential dilution from shares available for future issuance, which could weigh on shareholder value. Material related-party transactions totaling $3 million were paid to Kanders & Company, a firm solely owned by the CEO, for acquisition support. The proposed changes to the Board of Directors, with two current members not standing for re-election and two new/returning nominees, also represent a notable shift in governance. Investors should scrutinize these compensation practices, potential dilution, and related-party dealings.
At the time of this filing, CDRE was trading at $29.15 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $28.22 to $48.76. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.